We are live on
!
Find out more
SCM
Sio Capital Management Portfolio holdings
AUM
$604M
Turnover
53.26%
1-Year Est. Return
96.57%
This Fund
S&P 500
This Quarter
Est. Return
+1.53%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$505M
AUM Growth
+$162M
(+47%)
Cap. Flow
+$139M
Cap. Flow
% of AUM
27.48%
Top 10 Holdings %
Top 10 Hldgs %
36.69%
Holding
110
New
32
Increased
27
Reduced
17
Closed
21
Avg Time Held Equity + Options
0.5
years
Top 10 Avg Time Held Equity + Options
0.2
years
Top 20 Avg Time Held Equity + Options
0.3
years
Avg Time Held Equity only
0.5
years
Top 10 Avg Time Held Equity only
0.3
years
Top 20 Avg Time Held Equity only
0.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$19.7M |
| 2 |
Johnson & Johnson
JNJ
|
+$16.9M |
| 3 |
AMN Healthcare
AMN
|
+$14.3M |
| 4 |
Cigna
CI
|
+$14.3M |
| 5 |
ALBO
Albireo Pharma Inc
ALBO
|
+$13.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$8.84M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$8.57M |
| 3 |
R1 RCM Inc. Common Stock
RCM
|
+$8.51M |
| 4 |
Eli Lilly
LLY
|
+$7.54M |
| 5 |
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$6.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.63% |
| 2 | Miscellaneous | 16.98% |
| 3 | Consumer Staples | 0.82% |
| 4 | Financials | 0.57% |
| 5 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
PUT
Mesoblast
MESO
$1.82B
| $29.1M | 5.75% |
781,650
+461,050
| +144% | +$14.4M |
2020 Q1
2 quarters
|
|
2
SPDR Gold Trust
GLD
$141B
| $22.7M | 4.5% |
128,202
+7,500
| +6% | +$1.35M |
2020 Q1
2 quarters
|
|
3
Coherus Oncology
CHRS
$164M
| $19.1M | 3.79% |
1,044,161
-91,702
| -8% | -$1.71M |
2019 Q2
5 quarters
|
|
4
McKesson
MCK
$116B
| $17.6M | 3.49% |
118,449
+21,164
| +22% | +$3.21M |
2019 Q3
4 quarters
|
|
|
5
Johnson & Johnson
JNJ
$613B
| $17M | 3.37% |
+114,400
| New | +$16.9M |
2020 Q3
0 quarters
|
|
|
HRC
6
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
| $16.7M | 3.31% |
199,900
+109,900
| +122% | +$10.8M |
2020 Q2
1 quarter
|
|
|
ALBO
7
DELISTED
Albireo Pharma Inc
ALBO
| $16M | 3.16% |
+478,624
| New | +$13.9M |
2020 Q3
0 quarters
|
|
|
8
AMN Healthcare
AMN
$1.53B
| $15.9M | 3.15% |
+272,233
| New | +$14.3M |
2020 Q3
0 quarters
|
|
9
Cencora
COR
$65B
| $15.9M | 3.15% |
163,871
+63,326
| +63% | +$6.29M |
2019 Q3
4 quarters
|
|
10
PUT
CEL-SCI Corp
CVM
$30.4M
| $15.2M | 3.02% |
39,857
+28,827
| +261% | +$11.4M |
2019 Q3
4 quarters
|
|
11
Cardinal Health
CAH
$58.5B
| $15.1M | 3% |
322,480
+188,980
| +142% | +$9.7M |
2020 Q2
1 quarter
|
|
|
12
BioMarin Pharmaceuticals
BMRN
$10.9B
| $14.8M | 2.93% |
+194,744
| New | +$19.7M |
2020 Q3
0 quarters
|
|
|
13
Cigna
CI
$79B
| $13.8M | 2.73% |
+81,415
| New | +$14.3M |
2020 Q3
0 quarters
|
|
14
HCA Healthcare
HCA
$102B
| $13.2M | 2.62% |
105,932
+24,200
| +30% | +$3M |
2018 Q1
10 quarters
|
|
15
Molina Healthcare
MOH
$11.1B
| $12M | 2.38% |
65,774
+8,967
| +16% | +$1.63M |
2018 Q4
7 quarters
|
|
|
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $11.5M | 2.27% |
+147,500
| New | +$10.1M |
2020 Q3
0 quarters
|
|
17
DELISTED
Walgreens Boots Alliance
WBA
| $10.8M | 2.13% |
300,094
+175,900
| +142% | +$6.88M |
2020 Q2
1 quarter
|
|
18
PUT
Seres Therapeutics
MCRB
$25.5M
| $8.97M | 1.78% |
15,840
+13,065
| +471% | +$4.34M |
2020 Q2
1 quarter
|
|
19
Quest Diagnostics
DGX
$26.3B
| $8.59M | 1.7% |
+75,000
| New | +$8.86M |
2020 Q3
0 quarters
|
|
20
Teva Pharmaceutical Industries Limited
TEVA
$48.3B
| $8.57M | 1.7% |
951,691
-11,105
| -1% | -$117K |
2020 Q1
2 quarters
|
|
21
DELISTED
Cymabay Therapeutics
CBAY
| $8.39M | 1.66% |
1,159,236
-1,140,746
| -50% | -$6.1M |
2020 Q1
2 quarters
|
|
22
DELISTED
Radius Health, Inc.
RDUS
| $7.88M | 1.56% |
694,770
+332,368
| +92% | +$4.11M |
2019 Q4
3 quarters
|
|
|
SOLY
23
DELISTED
Soliton, Inc.
SOLY
| $7.83M | 1.55% |
1,025,000
| – | – |
2020 Q2
1 quarter
|
|
24
GSK
GSK
$98.7B
| $7.78M | 1.54% |
+165,310
| New | +$8.28M |
2020 Q3
0 quarters
|
|
25
Integer Holdings
ITGR
$4.31B
| $7.63M | 1.51% |
+129,376
| New | +$8.64M |
2020 Q3
0 quarters
|
|
Similar funds
EFL
V
MAM
RCM
AMG
VV
VCP
EHI
Sio Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Sio Capital Management held 110 positions worth $505M, up 47% from $343M the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Sio Capital Management deployed $139M of net new capital in Q3 2020, opening 32 new positions and adding to 27 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Miscellaneous and Consumer Staples.
On the sell side, the largest reduction was GW Pharmaceuticals Plc American Depositary Shares, an estimated $8.57M trimmed.
- Sio Capital Management's largest Q3 2020 buy was BioMarin Pharmaceuticals: 194,744 shares worth $14.8M.
- Sio Capital Management added most to HILL-ROM HOLDINGS, INC. in Q3 2020, an estimated $10.8M increase.
- Sio Capital Management's biggest Q3 2020 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $8.57M.
- Sio Capital Management fully exited Merck in Q3 2020, selling an estimated $8.84M.
- Sio Capital Management's ten largest holdings make up 37% of its $505M portfolio in Q3 2020.
- Sio Capital Management opened 32 new positions and closed 21 in Q3 2020.
- Sio Capital Management's portfolio value rose 47% quarter-over-quarter to $505M.
Based on Sio Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.